一种诱导干扰素的猪繁殖与呼吸综合征病毒疫苗候选株对猪异源强毒2型株VR-2385攻毒提供保护
为评估A2MC2第90代(A2P90)对异源强毒株的保护效果,40头3周龄猪随机分为5组,3周龄接种、8周龄攻毒。A2P90接种猪无病毒血症,15/16血清转阳且产生同源中和抗体(滴度8–128);对VR-2385攻毒可降低病毒血症和鼻排毒、减少肺病变、提高日增重,对MN184攻毒仅减少鼻排毒。
要点
- A2P90接种猪无病毒血症,15/16经ELISA血清转阳并产生同源中和抗体(滴度8–128)。
- VR-2385攻毒:接种组较未接种组显著降低病毒血症和鼻排毒、减少肺病变、提高日增重。
- MN184攻毒:无论接种与否均出现中重度临床疾病和病变,接种组仅dpd 5鼻排毒显著减少。
核心结论
- 在本研究条件下,A2P90疫苗株呈减毒状态、无 detectable 排毒、改善增重,并通过降低病毒载量和宏观肺病变对VR-2385攻毒猪提供保护。
- 需进一步研究不同免疫与攻毒方案,包括接种途径、剂量、时机和毒株。
研究设计与样本
- 研究将40头3周龄猪随机分为5组:NEG-CONTROL组(未接种未攻毒)、VAC-VR2385组(接种后VR-2385攻毒)、VR2385组(VR-2385攻毒)、VAC-MN184组(接种后MN184攻毒)和MN184组(MN184攻毒)。
- 3周龄接种,8周龄攻毒。
主要发现
- 所有接种猪均未检出病毒血症;至攻毒时,15/16接种猪经ELISA血清转阳,并产生针对同源株的中和抗体,滴度范围为8至128。
- VR-2385感染导致轻至中度临床疾病和病变;对VR-2385感染猪,接种较未接种显著降低攻毒后9天(dpd 9)的PRRSV病毒血症和鼻排毒,显著减少宏观肺病变,并显著提高平均日增重。
- MN184感染导致中至重度临床疾病和病变,无论接种状态如何;但接种猪在dpd 5时鼻排毒显著少于未接种猪。
局限性
- 需进一步研究不同免疫与攻毒方案,包括接种途径、剂量、时机和毒株。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Achieving consistent protection by vaccinating pigs against porcine reproductive and respiratory syndrome virus (PRRSV) remains difficult. Recently, an interferon-inducing PRRSV vaccine candidate strain A2MC2 was demonstrated to be attenuated and induced neutralizing antibodies. The objective of this study was to determine the efficacy of passage 90 of A2MC2 (A2P90) to protect pigs against challenge with moderately virulent PRRSV strain VR-2385 (92.3% nucleic acid identity with A2MC2) and highly virulent atypical PRRSV MN184 (84.5% nucleic acid identity with A2MC2). Forty 3-week old pigs were randomly assigned to five groups including a NEG-CONTROL group (non-vaccinated, non-challenged), VAC-VR2385 (vaccinated, challenged with strain VR-2385), VR2385 (challenged with strain VR-2385), VAC-MN184 (vaccinated, challenged with strain MN184) and a MN184 group (challenged with MN184 virus). Vaccination was done at 3weeks of age followed by challenge at 8weeks of age. No viremia was detectable in any of the vaccinated pigs; however, by the time of challenge, 15/16 vaccinated pigs had seroconverted based on ELISA and had neutralizing antibodies against a homologous strain with titers ranging from 8 to 128. Infection with VR-2385 resulted in mild-to-moderate clinical disease and lesions. For VR-2385 infected pigs, vaccination significantly lowered PRRSV viremia and nasal shedding by 9days post challenge (dpc), significantly reduced macroscopic lung lesions, and significantly increased the average daily weight gain compared to the non-vaccinated pigs. Infection with MN184 resulted in moderate-to-severe clinical disease and lesions regardless of vaccination status; however, vaccinated pigs had significantly less nasal shedding by dpc 5 compared to non-vaccinated pigs. Under the study conditions, the A2P90 vaccine strain was attenuated without detectable shedding, improved weight gain, and offered protection to the pigs challenged with VR-2385 by reduction of virus load and macroscopic lung lesions. Further work is needed to investigate different vaccination and challenge protocols, including routes, doses, timing and strains.
引用
- Fontanella E, Ma Z, Zhang Y, et al. An interferon inducing porcine reproductive and respiratory syndrome virus vaccine candidate elicits protection against challenge with the heterologous virulent type 2 strain VR-2385 in pigs. Vaccine. 2016. PMID: 27876202. doi:10.1016/j.vaccine.2016.11.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。